Research advances in non-small-cell lung cancerin ASCO

Chun-yan MA,Yong SONG
DOI: https://doi.org/10.3969/j.issn.1672-3384.2011.06.004
2011-01-01
Abstract:American society of clinical oncology(ASCO) recenfly published amounts of positive and negative clinical trial results of non-small-cell lung cancer(NSCLC),which poinedt out that the era of first-line therapy to unselected patients has gone with the wind.Maintenance therapy should also be applied to the right patients.Regarding second-line therapy,chemotherapy and targeted therapy both have individual advantages while the adjuvant therapy remained dominant in chemotherapy.Biomarkers-based targeted therapy may dramatically improve the patients' survival so the importance of biomarkers should be highlighted.
What problem does this paper attempt to address?